NZ722757B - Oxygen-Enriched Water Composition, Biocompatible Composition Comprising the Same, and Methods of Preparing and Using the Same - Google Patents
Oxygen-Enriched Water Composition, Biocompatible Composition Comprising the Same, and Methods of Preparing and Using the SameInfo
- Publication number
- NZ722757B NZ722757B NZ722757A NZ72275716A NZ722757B NZ 722757 B NZ722757 B NZ 722757B NZ 722757 A NZ722757 A NZ 722757A NZ 72275716 A NZ72275716 A NZ 72275716A NZ 722757 B NZ722757 B NZ 722757B
- Authority
- NZ
- New Zealand
- Prior art keywords
- oxygen
- enriched water
- water
- oxygen content
- water composition
- Prior art date
Links
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims abstract description 341
- 239000000203 mixture Substances 0.000 title claims abstract description 101
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims abstract description 460
- 239000001301 oxygen Substances 0.000 claims abstract description 459
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 459
- 230000002123 temporal effect Effects 0.000 claims abstract description 4
- 201000001431 hyperuricemia Diseases 0.000 claims description 27
- 239000004615 ingredient Substances 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 15
- 238000010438 heat treatment Methods 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 8
- 235000016236 parenteral nutrition Nutrition 0.000 claims description 7
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 3
- 239000011707 mineral Substances 0.000 claims description 3
- 229940088594 Vitamin Drugs 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- 239000003792 electrolyte Substances 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 2
- 229930003231 vitamins Natural products 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 description 43
- LEHOTFFKMJEONL-UHFFFAOYSA-N Trioxopurine Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 32
- 229940116269 Uric Acid Drugs 0.000 description 31
- 238000002360 preparation method Methods 0.000 description 14
- 238000006213 oxygenation reaction Methods 0.000 description 13
- 241000700159 Rattus Species 0.000 description 11
- 238000003860 storage Methods 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- QRSFFHRCBYCWBS-UHFFFAOYSA-N [O].[O] Chemical compound [O].[O] QRSFFHRCBYCWBS-UHFFFAOYSA-N 0.000 description 8
- 238000009825 accumulation Methods 0.000 description 8
- 239000002537 cosmetic Substances 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000000126 substance Substances 0.000 description 7
- 230000036826 Excretion Effects 0.000 description 6
- 235000013361 beverage Nutrition 0.000 description 6
- -1 chlorine ions Chemical class 0.000 description 6
- 230000029142 excretion Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000001965 increased Effects 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 230000003247 decreasing Effects 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 235000013373 food additive Nutrition 0.000 description 5
- 239000002778 food additive Substances 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000007928 intraperitoneal injection Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000001737 promoting Effects 0.000 description 5
- 238000004659 sterilization and disinfection Methods 0.000 description 5
- 210000004369 Blood Anatomy 0.000 description 4
- 230000003078 antioxidant Effects 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000036760 body temperature Effects 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 239000003651 drinking water Substances 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 230000002335 preservative Effects 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000000490 cosmetic additive Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 201000005569 gout Diseases 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000001954 sterilising Effects 0.000 description 3
- RYYCJUAHISIHTL-UHFFFAOYSA-N 5-azaorotic acid Chemical compound OC(=O)C1=NC(=O)NC(=O)N1 RYYCJUAHISIHTL-UHFFFAOYSA-N 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N Colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- 102000018251 EC 2.4.2.8 Human genes 0.000 description 2
- 108010091358 EC 2.4.2.8 Proteins 0.000 description 2
- 230000036740 Metabolism Effects 0.000 description 2
- 229950000193 Oteracil Drugs 0.000 description 2
- 206010038444 Renal failure chronic Diseases 0.000 description 2
- 239000006096 absorbing agent Substances 0.000 description 2
- 230000000844 anti-bacterial Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000003899 bactericide agent Substances 0.000 description 2
- 235000012206 bottled water Nutrition 0.000 description 2
- 201000000522 chronic kidney disease Diseases 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000000249 desinfective Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 235000021271 drinking Nutrition 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000002708 enhancing Effects 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 230000004634 feeding behavior Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000035786 metabolism Effects 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 235000020939 nutritional additive Nutrition 0.000 description 2
- 125000004430 oxygen atoms Chemical group O* 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N water-d2 Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- 230000002087 whitening Effects 0.000 description 2
- MBGGBVCUIVRRBF-UHFFFAOYSA-N 4-[2-(benzenesulfinyl)ethyl]-1,2-diphenylpyrazolidine-3,5-dione Chemical compound O=C1N(C=2C=CC=CC=2)N(C=2C=CC=CC=2)C(=O)C1CCS(=O)C1=CC=CC=C1 MBGGBVCUIVRRBF-UHFFFAOYSA-N 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N Allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 206010003885 Azotaemia Diseases 0.000 description 1
- 206010007027 Calculus urinary Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010018634 Gouty arthritis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 229920002521 Macromolecule Polymers 0.000 description 1
- 208000003067 Myocardial Ischemia Diseases 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N Probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 208000008425 Protein Deficiency Diseases 0.000 description 1
- 210000002966 Serum Anatomy 0.000 description 1
- 210000003491 Skin Anatomy 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229960003329 Sulfinpyrazone Drugs 0.000 description 1
- 108010092464 Urate Oxidase Proteins 0.000 description 1
- 206010046337 Urate nephropathy Diseases 0.000 description 1
- 208000009852 Uremia Diseases 0.000 description 1
- 208000008281 Urolithiasis Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002730 additional Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 201000001084 cerebrovascular disease Diseases 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000002848 electrochemical method Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000001771 impaired Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000002045 lasting Effects 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003287 optical Effects 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003595 spectral Effects 0.000 description 1
- 230000002195 synergetic Effects 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 230000003424 uricosuric Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 239000003064 xanthine oxidase inhibitor Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/54—Mixing with gases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F1/00—Treatment of water, waste water, or sewage
- C02F1/68—Treatment of water, waste water, or sewage by addition of specified substances, e.g. trace elements, for ameliorating potable water
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F1/00—Treatment of water, waste water, or sewage
- C02F1/72—Treatment of water, waste water, or sewage by oxidation
- C02F1/727—Treatment of water, waste water, or sewage by oxidation using pure oxygen or oxygen rich gas
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F2103/00—Nature of the water, waste water, sewage or sludge to be treated
- C02F2103/02—Non-contaminated water, e.g. for industrial water supply
- C02F2103/026—Treating water for medical or cosmetic purposes
Abstract
Provided is an oxygen-enriched water composition comprising water and oxygen, wherein: (a) the oxygen-enriched water composition comprises an oxygen content of no less than 20 ppm when the oxygen content of the oxygen-enriched water composition is measured at a temperature ranging from 4 oC to 50 oC; and (b) the oxygen content of the oxygen-enriched water composition has a temporal stability that is characterized by the following feature: provided that the oxygen content measured at a given time point t0 is 100%, the oxygen content measured at 30 minutes from the given time point t0 is A%, and the oxygen content measured at 180 minutes from the given time point t0 is B%, then a difference between A% and B% is less than 24%. ; and (b) the oxygen content of the oxygen-enriched water composition has a temporal stability that is characterized by the following feature: provided that the oxygen content measured at a given time point t0 is 100%, the oxygen content measured at 30 minutes from the given time point t0 is A%, and the oxygen content measured at 180 minutes from the given time point t0 is B%, then a difference between A% and B% is less than 24%.
Description
OXYGEN-ENRICHED WATER COMPOSITION, BIOCOMPATIBLE
COMPOSITION COMPRISING THE SAME, AND METHODS OF
PREPARING AND USING THE SAME
CROSS-REFERENCE TO RELATED APPLICATIONS
This Application claims the priority to Taiwan Patent Application No. 104127596, filed on
August 25, 2015, and Taiwan Patent Application No. 104128012, filed on August 26, 2015, both of
which are herein incorporated by reference in their entireties.
FIELD OF THE INVENTION
The present disclosure relates to an oxygen-enriched water composition and more particularly
to an oxygen-enriched water composition with stable oxygen content and small molecular clusters.
In addition, the present disclosure further provides a biocompatible composition containing the
oxygen-enriched water composition, a method of preparing oxygen-enriched water composition and
a use of oxygen-enriched water composition for treating and/or preventing hyperuricemia,
comprising hyperuricemia, gout and other diseases induced or caused by high uric acid level.
BACKGROUND OF THE INVENTION
Oxygen-enriched water generally refers to drinking water made by adding or introducing
active oxygen to clean and drinkable water. So far there is no unified definition for the oxygen
content of oxygen-enriched water, but generally water with oxygen content greater than or equal to
ppm is recognized as oxygen-enriched water.
Currently, there are more than hundreds of oxygen-enriched water manufacturers and
distributors, who claim their products are good for health and well-being, asserting that
oxygen-enriched water may significantly promote health if users constantly drink their products for
a long time.
However, commercially available oxygen-enriched water products are unstable and thus draw
many critiques on the efficacy of oxygen-enriched water. For example, some people argue that
oxygen-enriched water cannot sustain high oxygen content under human body temperature, such
that dissolved oxygen in the oxygen-enriched water will be released rapidly in gaseous form and
fail to achieve the intended benefits.
In this regard, it has been reported that oxygen-enriched water made by introduction of oxygen
followed by pressurization has higher oxygen content, and that decrease rates of oxygen content of
oxygen-enriched water made at different conditions do not differ much. However, current studies
haven’t proposed how to improve known processes to make oxygen-enriched water with high
stability for a long time and/or at high temperature (e.g. above 30 C).
SUMMARY OF THE INVENTION
In view of the problems mentioned above, the present disclosure provides an oxygen-enriched
water, a biocompatible composition containing oxygen-enriched water and a method of preparing
oxygen-enriched water, wherein the oxygen-enriched water has an oxygen content varying only
slightly over time and having high stability. In addition, even if the oxygen-enriched water of the
present disclosure is subject to a more stringent condition, such as high temperature, it may still
maintain higher dissolved oxygen, such as greater than 20 ppm or greater than 25 ppm, and
maintain a higher oxygen content even after a predetermined period of time.
The present disclosure also provides a use of oxygen-enriched water in the manufacture of a
medicament for treatment and/or prevention of hyperuricemia, i.e. a process of treating and/or
preventing hyperuricemia by using oxygen-enriched water, wherein the oxygen-enriched water has
an oxygen content varying only slightly over time and having high stability. In addition, even if the
oxygen-enriched water of the present disclosure is subject to a more stringent condition, such as
high temperature, it may still maintain higher dissolved oxygen, such as greater than 20 ppm or
greater than 25 ppm, and maintain a higher oxygen content even after a predetermined period of
time.
In one embodiment, the present disclosure provides an oxygen-enriched water comprising
water and oxygen, wherein the oxygen-enriched water has an oxygen content of no less than 20
ppm, and wherein given an initial oxygen content of the oxygen-enriched water as 100%, a
difference (A-B) between (A) an oxygen content percentage measured immediately after standing
the oxygen-enriched water for 30 minutes and (B) an oxygen content percentage measured
immediately after standing the oxygen-enriched water for 180 minutes is less than 24%.
In a preferred embodiment, the difference (A-B) is less than 20%, preferably less than 15%,
such as between 5% and 20%.
In a preferred embodiment, the oxygen-enriched water has an oxygen content of no less than
ppm, such as between 20 ppm and 50 ppm, or between 25 ppm and 50 ppm. In addition, in
another preferred embodiment, the oxygen-enriched water, even after standing for 180 minutes, has
an oxygen content of no less than 25 ppm.
In one embodiment, the oxygen-enriched water has, as measured by O NMR, a full width at
half maximum (FWHM) between 40 Hz and 80 Hz, preferably between 50 Hz and 70 Hz, such as
between 60 Hz and 70 Hz.
The present disclosure also provides an aforesaid oxygen-enriched water, wherein the oxygen
content is measured from the oxygen-enriched water at 0 C to 40 C, such as measured from the
oxygen-enriched water at 0 C to 12 C, preferably measured from the oxygen-enriched water at 4
o o o
C to 8 C (e.g. 6 C).
In a preferred embodiment, after heating the oxygen-enriched water from 10 C to 40 C, the
oxygen content change is less than 20%, preferably less than 10%.
In a preferred embodiment, after heating the oxygen-enriched water from 10 C to 40 C, the
oxygen content is no less than 25 ppm, preferably no less than 30 ppm.
In a preferred embodiment, after maintaining the oxygen-enriched water at a condition of 30
C to 40 C for 120 minutes, the oxygen content change is less than 30%, preferably less than 25%.
In a preferred embodiment, after maintaining the oxygen-enriched water at a condition of 30
C to 40 C for 120 minutes, the oxygen content is no less than 20 ppm, preferably no less than 25
ppm.
In a preferred embodiment, the oxygen-enriched water, even at a condition of 30 C to 40 C,
can still maintain high oxygen content (such as no less than 20 ppm, no less than 25 ppm or no less
than 30 ppm) for at least 60 minutes.
In a preferred embodiment, the oxygen-enriched water, even at a condition of about 37 C, can
still maintain high oxygen content (such as no less than 20 ppm, no less than 25 ppm or no less than
ppm) for at least 60 minutes, 90 minutes or 120 minutes.
In a preferred embodiment, the oxygen-enriched water may maintain an oxygen content of no
less than 25 ppm at a condition of greater than 40 C.
In a preferred embodiment, after heating the oxygen-enriched water from an initial temperature
o o o o
of 5 C to 10 C to a temperature of 40 C to 50 C, the oxygen content change is less than 20%,
such as less than 15%.
In a preferred embodiment, during the period of heating the oxygen-enriched water from an
o o o
initial temperature of 5 C to 10 C to 50 C, the oxygen content is constantly maintained at no less
than 25 ppm, such as no less than 30 ppm.
In one embodiment, the oxygen-enriched water of the present disclosure contains only water,
oxygen and non-artificially added ingredients.
The present disclosure also provides a biocompatible composition, which contains the
aforesaid oxygen-enriched water and at least one biocompatible ingredient.
For example, the biocompatible composition may be a pharmaceutical composition, a cosmetic
composition or a beverage composition, and the biocompatible ingredient may be one or more of a
parenteral nutrition, a therapeutic agent, a cosmetic additive and a food additive.
In one embodiment, the oxygen-enriched water is present as a pharmaceutical composition,
which is formulated as an oral dosage, an intravenous injection or an intravenous infusion to be
administered to a recipient with hyperuricemia.
In one embodiment, the pharmaceutical composition further comprises at least one therapeutic
agent for treating hyperuricemia.
The present disclosure also provides a method of preparing oxygen-enriched water, comprising
a step of supplying oxygen to a water body, characterized in that during oxygen supply, the water
body is maintained at a condition of 0 C to 12 C, and oxygen is continuously supplied to the water
body at a flow rate of 50 cc/min to 1000 cc/min for a period of time no less than 30 minutes.
In one embodiment, during oxygen supply, the water body is maintained at a condition of 4 C
to 8 C, such as 6 C.
In one embodiment, the volume of the water body ranges from 1 liter to 15 liter, and/or the
oxygen supply duration is no less than 180 minutes, such as about 210 minutes.
In one embodiment, during oxygen supply, oxygen is supplied to the water body at a first flow
rate until the oxygen content of the water body ranges from 20 ppm to 25 ppm, and then oxygen is
supplied to the water body at a second flow rate less than or equal to the first flow rate. For
example, the first flow rate is no less than 50 cc/min, and the second flow rate is no greater than
1000 cc/min.
The present disclosure also provides an oxygen-enriched water prepared by the aforesaid
method.
Specifically, this invention further provides an oxygen-enriched water composition comprising
water and oxygen, wherein: (a) the oxygen-enriched water composition comprises an oxygen
content of no less than 20 ppm when the oxygen content of the oxygen-enriched water composition
is measured at a temperature ranging from 4 C to 50 C; and (b) the oxygen content of the
oxygen-enriched water composition has a temporal stability that is characterized by the following
feature: provided that the oxygen content measured at a given time point t is 100%, the oxygen
content measured at 30 minutes from the given time point t is A%, and the oxygen content
measured at 180 minutes from the given time point t is B%, then a difference between A% and B%
is less than 24%.
In one embodiment, the oxygen content measured at 180 minutes from the given time point t
is no less than 25 ppm.
In one embodiment, the oxygen content of the oxygen-enriched water composition has a
temperature stability that is characterized by the following feature: a decrease in the oxygen content
is less than 20% when the oxygen-enriched water composition is heated from a temperature of 10
C to a temperature of 40 C.
In one embodiment, the oxygen content of the oxygen-enriched water composition has a
temperature stability that is characterized by the following feature: the oxygen content is no less
than 25 ppm when the oxygen-enriched water composition is heated from a temperature of 10 C to
a temperature of 40 C.
In one embodiment, the oxygen content of the oxygen-enriched water composition has a
temperature stability that is characterized by the following feature: a decrease in the oxygen content
is less than 30% when the oxygen-enriched water composition is placed under a temperature
ranging from 30 C to 40 C for at least 120 minutes.
In one embodiment, the oxygen content of the oxygen-enriched water composition has a
temperature stability characterized by the following feature: the oxygen content is maintained at no
less than 20 ppm when the oxygen-enriched water composition is placed under a temperature
ranging from 30 C to 40 C for at least 60 minutes.
In one embodiment, the oxygen content of the oxygen-enriched water composition has a
temperature stability that is characterized by the following feature: a decrease in the oxygen content
is less than 20% when the oxygen-enriched water composition is heated from a temperature ranging
o o o o
from 5 C to 10 C to a temperature ranging from 40 C to 50 C.
In one embodiment, the oxygen content of the oxygen-enriched water composition has a
temperature stability that is characterized by the following feature: the oxygen content is maintained
at no less than 30 ppm during the process of heating the oxygen-enriched water composition from a
o o o o
temperature ranging from 5 C to 10 C to a temperature ranging from 40 C to 50 C.
In one embodiment, the oxygen-enriched water composition is characterized by having a full
width at half maximum between 40 Hz and 80 Hz when the oxygen-enriched water composition is
measured with O NMR.
In one embodiment, provided is a method of promoting excretion of uric acid and/or reducing
blood uric acid level in a subject in need thereof, comprising administering to the subject in need
thereof an effective amount of the oxygen-enriched water composition. Furthermore, provided is a
use of the oxygen-enriched water composition for treating and/or preventing hyperuricemia, such as
for promoting excretion of uric acid and/or reducing blood uric acid level in a subject in need
thereof; also provided is a use of the oxygen-enriched water composition in the manufacture of a
medicament for treatment and/or prevention of hyperuricemia, such as for promoting excretion of
uric acid and/or reducing blood uric acid level in a subject in need thereof.
DESCRIPTION OF THE EMBODIMENTS
To enable those skilled in the art to further appreciate the features and effects of the present
disclosure, words and terms contained in the specification and appended claims are described and
defined. Unless otherwise defined, all technical and scientific terms used herein have the same
meaning as commonly understood by those of ordinary skill in the art to which this disclosure
pertains. In the case of conflict, the present document and definitions contained herein will control.
Theories or mechanisms described and disclosed herein, whether they are right or wrong,
should in no way limit the scope of the present disclosure so long as the present disclosure may be
practiced without regard for any particular theory or mechanism.
The use of “a,” “an” or similar expression is employed to describe elements and features
described herein. This is done merely for convenience and to give a general sense of the scope of
the present disclosure. Accordingly, this description should be read to include one or at least one
and the singular also includes the plural unless it is obvious to mean otherwise.
As used herein, the term “comprises,” “comprising,” “includes,” “including,” “has,” “having”
or any other variant thereof is construed as an open-ended transitional phrase intended to cover a
non-exclusive inclusion. For example, a composition or manufacture that comprises a list of
elements is not necessarily limited to only those elements but may include other elements not
expressly listed or inherent to such composition or manufacture. Further, unless expressly stated to
the contrary, the term “or” refers to an inclusive or and not to an exclusive or. For example, a
condition “A or B” is satisfied by any one of the following: A is true (or present) and B is false (or
not present), A is false (or not present) and B is true (or present), and both A and B are true (or
present). In addition, whenever open-ended transitional phrases are used, such as “comprises,”
“comprising,” “includes,” “including,” “has,” “having” or any other variant thereof, it is understood
that transitional phrases such as “consisting essentially of” and “consisting of” are also disclosed
and included.
In this disclosure, temperature, flow rate, value, amount and content and concentration of
ingredients are generally presented as a range or a percentage range; however, the description in
range or percentage range format is merely for convenience and brevity and therefore should be
interpreted as encompassing and specifically disclosing all possible subranges and individual
numerals or values therein, particularly all integers therein. For example, a range of “1 to 8” or
“between 1 and 8” should be understood as explicitly disclosing all subranges such as 1 to 7, 2 to 8,
2 to 6, 3 to 6, 4 to 8, 3 to 8 and so no, particularly all subranges defined by integers, as well as
disclosing all individual values such as 1, 2, 3, 4, 5, 6, 7 and 8. Unless otherwise defined, the
aforesaid interpretation rule should be applied throughout the present disclosure regardless
broadness of the scope.
Whenever amount, concentration or other numeral or parameter is expressed as a range, a
preferred range or a series of upper and lower limits, it is understood that all ranges defined by any
pair of the upper limit or preferred value and the lower limit or preferred value are specifically
disclosed, regardless whether these ranges are explicitly described or not. In addition, unless
otherwise defined, whenever a range is mentioned, the range should be interpreted as inclusive of
the endpoints and every integers and fractions in the range.
Given the intended purposes and advantages of this disclosure are achieved, numerals or
figures have the precision of their significant digits. For example, 40.0 should be understood as
covering a range of 39.50 to 40.49.
As used herein, a Markush group or a list of items is used to describe examples or
embodiments of the present disclosure. A skilled artisan will appreciate that all subgroups of
members or items and individual members or items of the Markush group or list can also be used to
describe the present disclosure. For example, when X is described as being “selected from a group
consisting of X , X and X ,” it is intended to disclose the situations of X is X and X is X and/or
1 2 3 1 1
X . In addition, when a Markush group or a list of items is used to describe examples or
embodiments of the present disclosure, a skilled artisan will understand that any subgroup or any
combination of the members or items in the Markush group or list may also be used to describe the
present disclosure. Therefore, when X is described as being “selected from a group consisting of X ,
X and X ” and Y is described as being “selected from a group consisting of Y , Y and Y ,” the
2 3 1 2 3
disclosure of any combination of X is X and/or X and/or X and Y is Y and/or Y and/or Y is
1 2 3 1 2 3
fully presented.
As used herein, unless otherwise specified, “water” means H O, which is generally present as
liquid but may also include other physical states such as solid ice. In addition, “water” as used
herein refers to substance primarily composed of H O molecules at ambient temperature and
ambient pressure; it is generally used as liquid medium and may contain other ingredients or
constituents, such as oxygen, trace elements, like calcium, magnesium, potassium, sodium and
chlorine ions, and/or impurities, but not limited thereto; these ingredients or constituents are
generally present in water naturally during the formation of water but not added artificially.
Therefore, in this disclosure, “water” encompasses both pure substance consisting of H O
molecules and composition or mixture containing H O molecules as carriers or media and other
ingredients.
As used herein, unless otherwise specified, terms “composition” and “combination” are used
interchangeably to refer to a matter primarily consisting of one or generally a plurality of
constituents, ingredients, compounds or substances. A composition is a man-made product, and the
type, amount, and physical state of the constituents, ingredients, compounds or substances
contained in the composition is generally controlled, selected or limited artificially.
As used herein, unless otherwise specified, “oxygen-enriched” and “oxygenated” are used
interchangeably as adjectives to describe that a noun, such as water, is modified artificially to make
its oxygen content, oxygen concentration or dissolved oxygen higher than its natural state or before
artificial intervention. Unless otherwise specified, “oxygen-enriched water” and “oxygenated
water” are used interchangeably. In addition, oxygen content, oxygen concentration and dissolved
oxygen are collectively referred to as oxygen saturation, a term used to describe the amount or
content of oxygen in a medium, such as water, which is calculated by dividing the oxygen content,
oxygen concentration or dissolved oxygen of a medium with the maximum achievable oxygen
content, oxygen concentration or dissolved oxygen of the medium under the same condition.
As used herein, “oxygen-enriched water” and “oxygen-enriched water composition” are used
interchangeably.
As used herein, “dissolved oxygen,” “dissolved oxygen degree,” “dissolved oxygen amount”,
“oxygen content” and similar variations thereof are used interchangeably to refer to the oxygen
content per liter medium, such as water, having a unit of mg/L or ppm. Methods of measuring
dissolved oxygen include electrochemical method, optical method, colorimetry, and titration, and
there are already many instruments commercially available for dissolved oxygen measurement.
As used herein, “hyperuricemia” refers to a disease, physical condition or state associated to
high serum uric acid, for example higher than 6.8 mg/dL for male and higher than 6.0 mg/dL for
female, including but not limited to gout, gouty arthritis, cerebrovascular accident, ischemic heart
disease, impaired kidney function, uremia, urolithiasis, urate nephropathy, chronic kidney disease
(CKD), hypoxanthine-guanine phosphoribosyltransferase (HGPRT) deficiency, hypertension and
nephrolithiasis.
As used herein, “biocompatible” refers to not causing severe adverse effects when being
applied to an organism such as human, and “biocompatible composition” refers to a composition
comprising the oxygen-enriched water according to the present disclosure, in which the
oxygen-enriched water acts primarily as the medium or vehicle for at least one biocompatible
ingredient.
As used herein, “pharmaceutical composition” refers to a composition containing the
oxygen-enriched water according to the present disclosure used for medical purposes. The
pharmaceutical composition may comprise another one or more biocompatible ingredients to
provide or enhance medical efficacy, such as a parenteral nutrition or therapeutic agent.
As used herein, “cosmetic composition” refers to a composition containing the
oxygen-enriched water according to the present disclosure used for cosmetic purposes. The
cosmetic composition may comprise another one or more biocompatible ingredients to provide or
enhance cosmetic efficacy, such as at least one of surfactant, powder, pigment, dye, alcohol,
tackifier, chelant, silicone compound, antioxidant, UV absorber, UV reflector, whitening agent,
humectant, fragrance, preservative, neutralizer, and pH modifier, but not limited thereto.
As used herein, “beverage composition” refers to an edible or drinkable composition
containing the oxygen-enriched water according to the present disclosure, which generally
comprises, for sales purpose, another one or more biocompatible ingredients, i.e. edible ingredients,
such as food additives; examples of food additives comprise without limitation to preservative,
bactericide, antioxidant, nutritional additive, flavoring agent, acidulant, colorant, spice, sweetener,
pasting agent, and emulsifier.
In the present disclosure, unless otherwise specified, physical or chemical properties are
measured at ambient pressure, i.e. about 1 atm.
In the present disclosure, unless otherwise specified, physical or chemical properties are
measured at ambient temperature or room temperature, i.e. about 25 C to 27 C.
As used herein, unless otherwise specified, “stand” or “standing” refers to placing something
in an environment without artificial intervention such as agitation, vibration, oscillation or shaking
for a period of time, such as 5 minutes, 10 minutes, 30 minutes, 45 minutes, 60 minutes, 90
minutes, 120 minutes, 6 hours, 1 day, several days, one week, or several weeks. The
oxygen-enriched water may be stood at a substantially constant temperature condition to maintain
the temperature of the oxygen-enriched water substantially constant, such as by standing it at a
thermally insulated condition such as in a vacuum bottle; alternatively, the oxygen-enriched water
may be stood in an open space with a substantially constant temperature, in which artificial heat
control is used to maintain the temperature of the space. In addition, the oxygen-enriched water may
also be stood in an environment without temperature control, such as an ambient temperature
condition, to allow the temperature of the oxygen-enriched water to change from its initial
o o o o o o o o o o o
temperature, such as 0 C, 2 C, 4 C, 6 C, 8 C, 10 C, 12 C, 15 C, 20 C, 30 C, or 40 C, to the
ambient temperature.
The present disclosure is further described in conjunction with the embodiments and examples
below. It is understood that these embodiments and examples are merely exemplary without
limiting the scope of the present disclosure or applications thereof. In addition, the present
disclosure is not limited to any theory described in the foregoing background or summary or the
following detailed description of embodiments or examples.
EXAMPLE: PREPARATION OF OXYGEN-ENRICHED WATER
To prepare oxygen-enriched water according to the present disclosure, any water body may be
supplied with oxygen or oxygenated according to a specific condition described in detail below.
In the present disclosure, water body suitable for oxygen supply treatment, also known as
“oxygenation,” may be a pretreated or non-pretreated water body, including but not limited to any
commercially available bottled water, tap water, mineral water, pure water, distilled water,
magnetized water, electrolyzed water, ionized water, ecological water, reverse osmosis water, and
any potable water. Unless otherwise specified, the aforesaid water body may refer to a water body
mainly consisting of water and a water body containing both water and ingredients other than water,
such as a water body containing water as the main medium and other additives, like various
beverages.
As oxygen supply means for supplying oxygen, examples can be referred from a Chinese
utility model patent of the present applicant No. 202705029, which is incorporated herein by
reference in its entirety. In generally, a conventional air compressor can be used to compress air,
and the compressed air can be passed through a molecular sieve to adsorb nitrogen in the
compressed air and output high purity oxygen.
In conjunction with the oxygen-enriched water preparation method according to the present
disclosure, the oxygen supply means is preferably a continuous oxygen supplier which operates
continuously to output oxygen continuously. Alternatively, the oxygen supply means may also be a
quantitative oxygen storage device, such as a conventional high-pressure oxygen cylinder which
continuously outputs oxygen at a predetermined flow rate for at least a period of time, such as 30
minutes, 60 minutes, 120 minutes, 180 minutes or 210 minutes. Suitable flow rate according to the
present disclosure is described in detail below.
Specifically, oxygen outputted by the oxygen supply means may be pure oxygen or gas with
high concentration oxygen for example greater than 80%, 85%, 90% or 95%, but not limited
thereto.
During oxygenation or oxygen supply, the water body is placed in a container, and an oxygen
supplier provides oxygen thereto continuously from the bottom of the water body. In addition, the
water body can be placed in a larger container from which it is supplied or transferred to a smaller
container communicated thereto and oxygenated by an oxygen supplier continuously. During
oxygenation, the container holding the water body may be opened, substantially closed or
completely closed.
As an example, water dispenser structures disclosed in the Chinese utility model patents of the
present applicant No. 202820947 and 202932748 are incorporated herein by reference in their
entirety.
To enable easy access of the processed or oxygen-enriched water to users, the oxygen supplier
and the water body container can be embodied as a water fountain or a water dispenser, wherein a
first water body container may be a water supplier capable of supplying water to a second water
body container, such as a cold-water reservoir of a water dispenser, to which oxygen is
continuously supplied by the oxygen supplier. Accordingly, oxygen-enriched water made by using
the method of preparing oxygen-enriched water according to the present disclosure can be
conveniently accessed and used by users.
In one embodiment, the water dispenser comprises a base in which a water supplier and an
oxygen producer are arranged, wherein the base is provided with a receiving space and a bottom
fixedly disposed with a support, and the base has a top portion centrally and downwardly recessed
to form an opening to be inserted by a water barrel.
The water supplier has a frame disposed in the receiving space and positioned at the base. A
water tank is mounted on the frame, and a water inlet channel aligned with and communicated to
the opening is provided at the center of the top base mounted on the storage space; the center of the
water inlet channel is provided with a push head extending upward and inserted into the water
barrel to allow drinking water contained therein to flow into the storage space. The top base is
further provided a vertically arranged through hole at the outer periphery of the water inlet channel,
and at least one water nozzle is arranged in front of the frame in communication with the water tank
for dispensing the drinking water.
The oxygen producer is disposed in the receiving space of the base and provided on the
support rack with an air compressor, a solenoid, at least one oxygen production tank and a storage
tank. The solenoid is communicated with the air compressor and the oxygen production tank, and
the oxygen production tank is communicated with the storage tank. The storage tank is connected
with a transport pipe extending upward and inserting into the water storage tank from above, and
the transport pipe is passed through the through hole on the top base into the storage space and is
provided at the terminal with an aeration pipe.
In one embodiment, the water dispenser further comprises a sterilization or disinfection device,
such as a UV tube, arranged on the inner wall of the water storage tank or around the opening of the
water outlet of the water dispenser to provide users with sterile and safe oxygen-enriched water.
Depending on the end use of oxygen-enriched water, the type and amount of the sterilization or
disinfection device may vary. For example, medical purpose oxygen-enriched water generally
requires a higher sterilization standard.
While several different oxygen-enriched waters and preparation methods are known in the art,
the inventor of the present application unexpectedly found that, with proper control of some
parameters and conditions, oxygen-enriched water with high stability can be made. As such, the
present disclosure provides a method of preparing oxygen-enriched water, comprising a step of
supplying oxygen to a water body, characterized in that during oxygen supply, the water body is
maintained at a condition of 0 C to 12 C, and oxygen is supplied to the water body at a flow rate
of 50 cc/min to 1000 cc/min for a period of time no less than 30 minutes.
Specifically, the inventor of the present application unexpectedly found that, with proper
control of the temperature of water body, oxygen flow rate and oxygenation time, the stability of the
oxygen-enriched water may be greatly increased, and oxygen-enriched water thus made has an
oxygen content changing relatively slightly under specific conditions.
In general, the volume of water body used in the aforesaid preparation method is not
particularly limited. In mass production, the volume of water body may be hundreds of liters,
thousands of liters or more. For household use, if the preparation method is implemented or
embodied as a water dispenser, in view of the size of the water dispenser, the volume of the water
body may be tens milliliters to several liters, such as 100 mL, 200 mL, 500 mL, 1 L, 2 L, 3 L, 5 L, 8
L, 10 L, 15 L, etc., depending on the volume of the water storage tank or cold-water reservoir of the
water dispenser. In one embodiment, the volume of water body ranges from 1 L to 15 L.
In the aforesaid preparation method, the processing temperature is preferably between 0 C to
12 C, and water body maintained at this temperature range during oxygen supply may achieve
higher maximum dissolved oxygen. In particular, the inventor of the present application
unexpectedly found that the optimal oxygen dissolution effect is achieved at a temperature between
4 C and 8 C, such as the maximum dissolved oxygen of about 60 ppm, 55 ppm or 50 ppm. In a
preferred embodiment, the water body is maintained at about 6 C during oxygen supply.
In the aforesaid preparation method, the inventor of the present application unexpectedly found
that, as to the flow rate of oxygen supply, excessively high oxygen flow rate is not advantageous to
the stability of oxygen-enriched water obtained but is disadvantageous under some conditions.
Conversely, in the preparation method, a flow rate of 50 cc/min to 1000 cc/min is used to supply
oxygen to the water body to obtain oxygen-enriched water with high stability.
Given an ordinary water body having an oxygen content of about 3 ppm to 5 ppm, the inventor
found that, during oxygen supply of the preparation method, before the oxygen content of the water
body reaches about 20 ppm to 25 ppm, increased oxygen content per minute (ppm/min) increases as
the oxygen flow rate increases. However, after the oxygen content of the water body reaches about
ppm to 25 ppm, increased oxygen content per minute is not significantly influenced by the
oxygen flow rate. On the contrary, under some circumstances, excessively high flow rate, such as
greater than 1500 cc/min, of oxygen supply is not beneficial to increasing the stability of
oxygen-enriched water. Therefore, the preparation method according to the present disclosure may
use a flow rate of 50 cc/min to 1000 cc/min to supply oxygen to the water body, such as using a
fixed low flow rate constantly to perform oxygen supply, such as 50 cc/min, 100 cc/min, 150
cc/min, 200 cc/min, 250 cc/min, 300 cc/min, 400 cc/min, 500 cc/min or 1000 cc/min, but not
limited thereto. Therefore, the method according to the present disclosure may produce an
oxygen-enriched water with an oxygen content 4-fold or 5-fold greater than an ordinary water body.
In one embodiment, during oxygen supply, two or more different flow rates can be employed.
For example, during oxygen supply, a first flow rate is used until the oxygen content of the water
body reaches 20 ppm to 25 ppm; next, a second flow rate, which is less than or equal to the first
flow rate, is subsequently used for oxygen supply. For example, the first flow rate is no less than 50
cc/min, and the second flow rate is no greater than 1000 cc/min.
In the aforesaid preparation method, regarding oxygen supply time, the inventor unexpectedly
found that, instead of using a high flow rate and a high pressure to make the oxygen-enriched water
within a short period of time, the present disclosure, by using long-term continuous oxygen supply
to water body, may produce oxygen-enriched water with enhanced stability. Therefore, in one
embodiment, the oxygen supply time is no less than 30 minutes, such as 45 minutes, 60 minutes, 90
minutes, 120 minutes, 150 minutes, 180 minutes, 210 minutes or 240 minutes. In one embodiment,
the oxygen supply time is 60 minutes to 240 minutes. In one embodiment, when the increased
oxygen content per minute of the water body is less than for example 0.01 ppm/min, the oxygen
content of the water body is close to saturation, such that the oxygen-enriched water thus made can
be drunk immediately or bottled for subsequent drinking.
Therefore, the preparation method according to the present disclosure, by controlling the
temperature of water body, oxygen supply flow rate and oxygen supply time, may be used for
oxygenation of water bodies of any volume, so as to prepare oxygen-enriched water with excellent
stability.
EXAMPLE: PROPERTY ANALYSIS OF OXYGEN-ENRICHED WATER
To further confirm the physical and chemical properties of the oxygen-enriched water made by
the method according to the present disclosure, a water body of a predetermined volume, such as
3.7 L or 1 gallon, is poured to the cold-water reservoir of the aforesaid water dispenser, in which the
temperature of the water body is maintained by a cooling circuit at for example 6 C, and
oxygenation at a predetermined flow rate, such as about 200 cc/min, is performed for a period of
time, such as about 210 minutes. After the completion of oxygenation, an oxygen-enriched water
according to one embodiment of the present disclosure is made.
To analyze the property of the oxygen-enriched water prepared according to the
aforementioned method, a sample of 540 µL was prepared, and 60 µL of D O (heavy water) was
added to the sample. Then the sample was loaded into a 5 mm NMR tube as an experimental group.
Similarly, the above-mentioned procedure is followed to prepare a comparison group from a water
body of the same source without oxygenation.
The test was carried out at a room temperature, and the relative humidity was about 50%.
The following conditions and parameters were used by 11.74 Tesla NMR performing O
NMR analysis: resonance frequency 67.768 MHz, sampling time 0.345 second, data point 4096,
spectral bandwidth 5940.4 Hz, 4096 scans, flip angle ~67 , relaxation delay 0.2 second, tune and
match normal, 25 C constant temperature time>20 minutes, constant temperature airstream
velocity>600 liter/minute; wherein “ O” represents testing oxygen atom nucleus without
decoupling the hydrogen atom nucleus ( i.e. the pulse-acquire procedure), and “ O decoupling”
represents testing oxygen atom nucleus while decoupling the hydrogen atom nucleus ( i.e. the
inverse-gated procedure).
Major data processing parameters of the NMR experiment were as follows: not using line
broadening or any window function parameters, data point 8192, and complex fast Fourier
transform.
17 17
The result shows that the experimental group has a O FWHM of 64.16 Hz and a O
17 17
decoupling FWHM of 56.5 Hz, and the comparison group has a O FWHM of 107.65 Hz and a O
decoupling FWHM of 65.42 Hz.
Generally, the smaller the water molecular clusters, the lower the NMR FWHM value will be.
From the experimental data, it can be inferred that the oxygen-enriched water prepared according to
the present disclosure has smaller water molecular clusters to allow rapid osmosis into drinker’s
body and fast absorption to promote metabolism; meanwhile, it provides smoother and silky
mouthfeel.
In addition, without being bound by any theory, the inventor believes that in the
oxygen-enriched water prepared according to the present disclosure, around every 5 to 6 water
molecules are linked by hydrogen bonds to form a molecular cluster having for example about 5 to
10 hydrogen bonds, defining a cage-like molecular cluster formed by 6 water molecules and 8
hydrogen bonds or a prism-like molecular cluster formed by 6 water molecules and 9 hydrogen
bonds, so as to capture or surround the oxygen in the three-dimensional structure of the molecular
cluster to achieve higher stability of oxygen content.
EXAMPLE: MEASUREMENT OF MAXIMUM OXYGEN CONTENT OF
OXYGEN-ENRICHED WATER
Two bottles of different commercially available bottled mineral water obtained respectively
from Young Energy Source Co., Ltd. and Wellcome Department Store Co., Ltd. are used as a first
water body specimen and a second water body specimen, respectively having an initial oxygen
content of 3.7 ppm and 3.5 ppm before oxygenation. A predetermined volume, about 1 gallon, of
the aforesaid water body specimens are individually poured into the cold-water reservoir of the
water dispenser of the above-mentioned example, using a cooling circuit to maintain the
temperature of the specimens at around 4 C to 8 C, and oxygen supply or oxygenation is
performed at a flow rate of about 200 cc/min. During the oxygenation process, around 200 mL of
each water body specimen is periodically outputted and tested by a dissolved oxygen measurement
device WTW Oxi3210 in conjunction with a CellOx 325 electrode to measure the oxygen content at
room temperature. The result indicates that the first water body specimen reaches a maximum
oxygen content of about 38.5 ppm after oxygenation for about 208 minutes, and the second water
body specimen reaches a maximum oxygen content of about 37.8 ppm after oxygenation for about
220 minutes.
EXAMPLE: STABILITY ANALYSIS OF OXYGEN-ENRICHED WATER (I)
The foregoing first water body specimen and second water body specimen are oxygenated as
described above to obtain the first oxygen-enriched water and the second oxygen-enriched water,
from each of which a sample of about 200 mL is outputted and placed in an open space at room
temperature. The oxygen content of the first oxygen-enriched water and the second
oxygen-enriched water is measured periodically to observe the variation of oxygen content with
time, as shown in Table 1 below.
Oxygen content of 1st Oxygen content of 2nd
Elapsed time Relative oxygen Relative oxygen
oxygen-enriched water oxygen-enriched water
(hr) content percentage (%) content percentage (%)
(ppm) (ppm)
0 37.9 100 38.6 100
0.5 30.3 79.95 31.0 80.31
1 28.9 76.25 29.2 75.65
1.5 27.3 72.03 27.8 72.02
2 26.9 70.98 26.4 68.39
2.5 26.7 70.45 25.7 66.58
3 25.7 67.81 25.0 64.77
3.5 23.8 62.80 24.2 62.69
4 21.6 56.99 21.9 56.74
4.5 21.3 56.20 20.7 53.63
21.0 55.41 20.1 52.07
.5 20.7 54.62 19.7 51.04
6 20.5 54.09 19.2 49.74
6.5 20.2 53.30 19.0 49.22
7 20.2 53.30 18.9 48.96
7.5 20.1 53.03 18.7 48.45
8 20.1 53.03 18.6 48.19
8.5 20.0 52.77 18.5 47.93
9 19.9 52.51 18.4 47.67
9.5 19.8 52.24 18.3 47.41
19.7 51.98 18.2 47.15
.5 19.7 51.98 18.1 46.89
11 19.6 51.72 18.0 46.63
11.5 19.6 51.72 18.0 46.63
12 19.5 51.45 17.9 46.37
12.5 19.5 51.45 17.9 46.37
13 19.4 51.19 17.8 46.11
13.5 19.4 51.19 17.7 45.85
14 19.3 50.92 17.7 45.85
14.5 19.3 50.92 17.6 45.60
19.2 50.66 17.6 45.60
.5 19.2 50.66 17.5 45.34
16 19.1 50.40 17.5 45.34
16.5 19.1 50.40 17.4 45.08
17 19.0 50.13 17.4 45.08
17.5 19.0 50.13 17.3 44.82
18 18.9 49.87 17.4 45.08
18.5 18.9 49.87 17.3 44.82
19 18.9 49.87 17.2 44.56
19.5 18.8 49.60 17.2 44.56
18.8 49.60 17.1 44.30
.5 18.8 49.60 17.1 44.30
21 18.7 49.34 17.0 44.04
21.5 18.7 49.34 17.0 44.04
22 18.7 49.34 16.9 43.78
22.5 18.6 49.08 16.9 43.78
23 18.6 49.08 16.9 43.78
23.5 18.6 49.08 16.8 43.52
24 18.5 48.81 16.8 43.52
Table 1
As shown from the data above, during the first initial 30 minutes after the oxygen-enriched
water has been prepared, a greater decrease of oxygen content is observed, which is probably
because during the period oxygen dissolution has not reached a steady state, but a more stable
oxygen content is observed thereafter, and the extent of oxygen content decrease becomes less and
less with time. In addition, even in an open space at room temperature, given that the initial oxygen
content of the first oxygen-enriched water (37.9 ppm) and of the second oxygen-enriched water
(38.6 ppm) as 100%, it can be calculated that the oxygen content percentage measured immediately
after standing the oxygen-enriched water for 30 minutes (79.95% and 80.31% respectively) minus
the oxygen content percentage measured immediately after standing the oxygen-enriched water for
180 minutes (67.81% and 64.77% respectively) produces a difference of 12.14% and 15.54%
respectively; in addition, after standing for 180 minutes, the oxygen content measured is still greater
than or equal to 25 ppm, indicating the high stability of the oxygen-enriched water according to the
present disclosure.
EXAMPLE: STABILITY ANALYSIS OF OXYGEN-ENRICHED WATER (II)
The first oxygen-enriched water and the second oxygen-enriched water are prepared as
o o o o o o
described above and then respectively heated to 10 C, 15 C, 20 C, 25 C and 30 C to 40 C to
measure the oxygen content. The results are shown in Table 2 below.
Oxygen content of 1st Oxygen content of 2nd
Relative oxygen Relative oxygen
Temp. ( C) oxygen-enriched water oxygen-enriched water
content percentage (%) content percentage (%)
(ppm) (ppm)
34.9 100 37.0 100
35.9 102.87 37.0 100
37.0 106.02 38.5 104.05
36.3 104.01 40.6 109.73
33.7 96.56 30.9 83.51
31 33.7 96.56 29.8 80.54
32 33.4 95.70 29.8 80.54
33 33.2 95.13 29.8 80.54
34 33.5 95.99 29.8 80.54
33.3 95.42 29.9 80.81
36 33.1 94.84 29.9 80.81
37 32.7 93.70 29.9 80.81
38 32.6 93.41 29.9 80.81
39 32.4 92.84 29.8 80.54
40 32.4 92.84 29.9 80.81
Table 2
From Table 2, it can be observed that the oxygen content of the oxygen-enriched water
increases during the initial heating stage (15 C to 25 C), which is probably because that the
oxygen-enriched water has not reached a steady state when the preparation is just completed.
However, after entering a steady state, the oxygen content change of the oxygen-enriched water
becomes more stable. For the first oxygen-enriched water, the oxygen content change is less than
% after it is heated from 10 C to 40 C, and the oxygen content is always above 30 ppm during
the whole heating process; for the second oxygen-enriched water, the oxygen content change is less
than 20% after it is heated from 10 C to 40 C, and the oxygen content is always about 30 ppm or
higher.
EXAMPLE: STABILITY ANALYSIS OF OXYGEN-ENRICHED WATER (III)
The first oxygen-enriched water and the second oxygen-enriched water are prepared as
described above and then respectively heated from an initial temperature to about 37 C, 35 C and
C and held substantially under the temperatures; the oxygen content is then measured after 30,
60, 90 and 120 minutes, and the results are shown respectively in Table 3 (37 C), Table 4 (35 C)
and Table 5 (30 C).
Relative Relative
Oxygen content Oxygen content
oxygen oxygen
Elapsed time Temp. of 1st Elapsed time Temp. of 2nd
content content
(min) ( C) oxygen-enriched (min) ( C) oxygen-enriched
percentage percentage
water (ppm) water (ppm)
(%) (%)
Just prepared 8.9 37.4 X Just prepared 5.7 34.9 X
0 37.0 33.8 100 0 37.0 32.7 100
37.2 31.6 93.49 30 37.2 30.4 92.97
60 37.1 29.8 88.17 60 37.1 28.9 88.38
90 37.0 27.7 81.95 90 37.3 27.6 84.40
120 37.1 26.4 78.11 120 36.8 25.8 78.90
Table 3
Relative Relative
Oxygen content Oxygen content
oxygen oxygen
Elapsed time Temp. of 1st Elapsed time Temp. of 2nd
content content
(min) ( C) oxygen-enriched (min) ( C) oxygen-enriched
percentage percentage
water (ppm) water (ppm)
(%) (%)
8.9 37.1 X 8.7 34.9 X
Just prepared Just prepared
0 34.8 34.1 100 0 35.2 33.1 100
35.2 32.9 96.48 30 34.9 30.9 93.35
60 35.3 31.6 92.67 60 35.1 29.5 89.12
90 35.2 29.8 87.39 90 35.2 28.1 84.89
120 35.1 27.9 81.82 120 34.8 26.8 80.97
Table 4
Relative Relative
Oxygen content Oxygen content
oxygen oxygen
Elapsed time Temp. of 1st Elapsed time Temp. of 2nd
content content
(min) ( C) oxygen-enriched (min) ( C) oxygen-enriched
percentage percentage
water (ppm) water (ppm)
(%) (%)
Just prepared 8.9 37.4 X Just prepared 8.6 34.7 X
0 30.1 36.9 100 0 30.3 33.4 100
29.8 34.2 92.68 30 29.8 32.1 96.11
60 30.2 33.1 89.70 60 30.1 30.9 92.51
90 30.1 30.4 82.38 90 30.2 29.1 87.13
120 29.7 29.1 78.86 120 29.9 27.9 83.53
Table 5
As observed from the data in Table 3 to Table 5, the oxygen-enriched water according to the
present disclosure, after being maintained under a condition of 30 C to 40 C for 120 minutes, has
an oxygen content variation always less than 30%, preferably less than 25% and more preferably
less than 20%. In addition, the oxygen-enriched water according to the present disclosure, during
the period of being maintained under a condition of 30 C to 40 C for 120 minutes, has an oxygen
content consistently no less than 20 ppm, preferably no less than 25 ppm. Other the other hand, the
oxygen-enriched water according to the present disclosure, at a condition of 30 C to 40 C, can
maintain an oxygen content of no less than 20 ppm for at least 60 minutes, more preferably
maintain an oxygen content of no less than 25 ppm for at least 120 minutes at a condition of about
37 C.
Since the normal body temperature of human being is about 37 C, based on the data above, it
can be inferred that the oxygen-enriched water according to the present disclosure may maintain a
relatively high oxygen content at normal body temperature, such as maintaining an oxygen content
of no less than 25 ppm at a condition of 37 C for at least 120 minutes, a time sufficient to allow
circulation of the oxygen-enriched water in body while maintaining its high oxygen content, which
is advantageous for promoting the oxygen content of various body parts.
In addition, as a first comparative example and a second comparative example, commercially
available NATURAL BEAUTY healthcare oxygen-enriched water and HOPPER O
o o o
oxygen-enriched water are heated from the initial temperature to 37 C, 35 C and 30 C and
substantially maintained at the temperature conditions, followed by oxygen content measurement
after 30, 60, 90 and 120 minutes respectively. The results are shown below in Table 6 (37 C),
Table 7 (35 C) and Table 8 (30 C).
Oxygen Oxygen
Relative oxygen Relative oxygen
Elapsed time Temp content of 1st Elapsed time Temp content of
content content
(min) ( C) Comp. Ex. (min) ( C) 2nd Comp.
percentage (%) percentage (%)
(ppm) Ex. (ppm)
Just opened 26.6 23.5 X Just opened 25.4 17.2 X
0 37.0 21.1 100 0 37.0 13.3 100
37.3 19.4 91.94 30 37.2 11.1 83.46
60 37.1 16.5 78.20 60 37.3 10.2 76.69
90 36.9 14.9 70.62 90 36.9 8.9 66.92
120 37.3 12.1 57.35 120 37.2 7.8 58.65
Table 6
Oxygen Oxygen
Relative Relative
Elapsed time Temp content of 1st Elapsed time Temp content of
oxygen content oxygen content
(min) ( C) Comp. Ex. (min) ( C) 2nd Comp.
percentage (%) percentage (%)
(ppm) Ex. (ppm)
26.6 23.4 X 25.4 17.1 X
Just opened Just opened
0 35.1 21.3 100 0 35.1 13.2 100
34.8 19.1 89.67 30 34.8 11.2 84.85
60 34.9 16.9 79.34 60 34.9 10.3 78.03
90 35.3 15.1 70.89 90 35.3 9.3 70.45
120 35.2 13.2 61.97 120 35.2 8.2 62.12
Table 7
Oxygen Oxygen
Relative Relative
Elapsed time Temp content of 1st Elapsed time Temp content of
oxygen content oxygen content
(min) ( C) Comp. Ex. (min) ( C) 2nd Comp.
percentage (%) percentage (%)
(ppm) Ex. (ppm)
Just opened 26.6 23.6 X Just opened 25.4 17.3 X
0 30.3 21.9 100 0 29.8 13.4 100
29.8 19.7 89.95 30 30.1 11.6 86.57
60 30.1 17.6 80.37 60 30.2 10.5 78.36
90 30.2 16.5 75.34 90 29.9 9.6 71.64
120 29.7 14.3 65.30 120 30.1 8.7 64.93
Table 8
Based on the comparison of the examples of the present disclosure in Table 3 to 5 and the
comparative examples in Table 6 to 8, it is found that the oxygen-enriched water according to the
present disclosure has a higher oxygen content when it is placed at a relatively high temperature
(e.g. above 30 C) for 120 minutes, the oxygen content change is preferably less than 25% and more
preferably less than 20%, and the oxygen content is above 20 ppm and more preferably above 25
ppm after 120 minutes. On the other hand, the oxygen-enriched water of the comparative examples
fails to maintain a high oxygen content when they are placed at a relatively high temperature (e.g.
above 30 C) for 120 minutes, the oxygen content decreases about 35% to 43%, and the oxygen
content is below 15 ppm.
EXAMPLE: STABILITY ANALYSIS OF OXYGEN-ENRICHED WATER (IV)
The first oxygen-enriched water and the second oxygen-enriched water are prepared as
described above and then respectively heated from about 8 C to about 50 C, during which the
oxygen content change is recorded, as shown in Table 9.
Oxygen content of 1st Relative oxygen Oxygen content of 2nd Relative oxygen
Temp. ( C) oxygen-enriched water content percentage oxygen-enriched water content percentage
(ppm) (%) (ppm) (%)
8.4 34.9 100 37.1 100
34.9 100 37.0 99.73
11 34.9 100 36.3 97.84
12 35.5 101.72 36.0 97.04
13 35.5 101.72 36.5 98.38
14 35.6 102.01 36.9 99.46
35.9 102.87 37.0 99.73
16 36.1 103.44 37.2 100.27
17 36.4 104.30 37.6 101.35
18 36.9 105.73 38.0 102.43
19 37.2 106.59 38.5 103.77
37.0 106.02 38.5 103.77
21 37.2 106.59 39.2 105.66
22 37.2 106.59 39.6 106.74
23 37.0 106.02 39.8 107.28
24 36.6 104.87 40.4 108.89
36.3 104.01 40.6 109.43
26 35.2 100.86 40.4 108.89
27 34.3 98.28 40.7 109.70
28 33.9 97.13 38.6 104.04
29 33.9 97.13 37.7 101.62
33.7 96.56 36.9 99.46
31 33.7 96.56 36.1 97.30
32 33.4 95.70 35.4 95.42
33 33.2 95.13 34.9 94.07
34 33.5 95.99 34.6 93.26
33.3 95.42 34.3 92.45
36 33.1 94.84 34.1 91.91
37 32.7 93.70 33.8 91.11
38 32.6 93.41 33.5 90.30
39 32.4 92.84 33.3 89.76
40 32.4 92.84 33.2 89.49
41 32.2 92.26 33.1 89.22
42 32.1 91.98 32.8 88.41
43 32.0 91.69 32.7 88.14
44 32.0 91.69 32.5 87.60
45 32.1 91.98 32.5 87.60
46 31.9 91.40 32.4 87.33
47 31.7 90.83 32.4 87.33
48 31.6 90.54 32.2 86.79
49 31.5 90.26 32.1 86.52
50 31.1 89.11 32.0 86.25
Table 9
From Table 9, it can be observed that the oxygen-enriched water according to the present
disclosure, after being heated from the initial temperature to a high temperature, shows a relatively
high oxygen content. For example, when the oxygen-enriched water is heated from an initial
o o o o
temperature of 5 C to 10 C to a temperature of 40 C to 50 C, the oxygen content change is less
than 20%, and during the heating process the oxygen content is always no less than 25 ppm. In
addition, when the oxygen-enriched water is heated from an initial temperature of 5 C to 10 C to a
temperature of 40 C to 50 C, the oxygen content change is preferably less than 15%, and during
the heating process the oxygen content is maintained preferably no less than 30 ppm.
As shown by the examples and embodiments above, the oxygen-enriched water of the present
disclosure has a higher stability and higher dissolved oxygen after preparation. The oxygen content
changes only slightly with time and/or at a condition of relatively high temperature (e.g. 37 C body
temperature), and the oxygen content is preferably maintained above 25 ppm, which is suitable for
directly drinking as well as subsequent processing to make various compositions to be provided or
administered to human body via various routes, such as intravenous injection, intravenous infusion,
oral administration, skin application (transdermal) and so on.
In one embodiment, the oxygen-enriched water made by the method above according to the
present disclosure is formulated as a biocompatible composition, which comprises the
oxygen-enriched water of the present disclosure and at least one biocompatible ingredient.
EXAMPLE: PHARMACEUTICAL COMPOSITION
In this example, oxygen-enriched water made by the method according to the present
disclosure is formulated as a pharmaceutical composition, wherein the biocompatible ingredient is
parenteral nutrition and/or therapeutic agent.
For example, various known parenteral nutrition may be added to the oxygen-enriched water
thus prepared. The parenteral nutrition may be at least one of amino acid, fat, saccharide,
electrolyte, vitamin, mineral and a combination thereof. For example, the parenteral nutrition may
be a 5% conc. dextrose (e.g. glucose) solution or a 0.9% conc. sodium chloride solution for
providing a pharmaceutical composition suitable for intravenous infusion.
In addition, for example, at least one known small molecule or macromolecule therapeutic
agent may be added to the oxygen-enriched water prepared as above to obtain a disease-treating
pharmaceutical composition. The therapeutic agent applicable is not particularly limited as long as
it is suitable for a formulation in aqueous solution form.
In one embodiment, the small molecule therapeutic agent is a therapeutic agent for treating
hyperuricemia, such as a xanthine oxidase inhibitor or uricosuric medication. In one embodiment,
the therapeutic agent for treating hyperuricemia is selected from the group consisting of allopurinol,
benzbromazone, sulfinpyrazone, probenecid, colchicine and a combination thereof, but not limited
thereto. In another embodiment, the therapeutic agent for treating hyperuricemia useful in
conjunction with the oxygen-enriched water of the present disclosure refers to any therapeutic agent
capable of producing additional or synergistic effect when used with the oxygen-enriched water.
EXAMPLE: COSMETIC COMPOSITION
In this example, oxygen-enriched water made by the method according to the present
disclosure is formulated as a cosmetic composition, wherein the biocompatible ingredient is any
common cosmetic additive. For example, the cosmetic additive may be at least one of surfactant,
powder, pigment, dye, alcohol, tackifier, chelant, silicone compound, antioxidant, UV absorber, UV
reflector, whitening agent, humectant, fragrance, preservative, neutralizer, pH modifier, and a
combination of any two or more thereof, but not limited thereto.
The cosmetic composition is generally for external use, such as being applied to a portion of
human body in need.
EXAMPLE: BEVERAGE COMPOSITION
In this example, oxygen-enriched water made by the method according to the present
disclosure is formulated as a beverage composition, and the biocompatible ingredient is any
common food additive. Examples of the food additive comprise without limitation to preservative,
bactericide, antioxidant, nutritional additive, flavoring agent, acidulant, colorant, spice, sweetener,
pasting agent, emulsifier, and a combination of any two or more thereof.
Therefore, the beverage composition containing the oxygen-enriched water according to the
present disclosure can be bottled or canned for sales.
EXAMPLE: EFFECT OF OXYGEN-ENRICHED WATER ON ANIMAL URIC ACID
METABOLISM
Wistar-strain male rats aged 7 to 8 weeks and weighed 280 to 300 g are subject to uric acid
experiments below. Body weight difference of rats in the group is less than 20%.
Once obtained, the rats are fed and observed for two weeks to allow them to adapt to the
environment and grow normally before the experiments begin. Conditions during the experiments
are as follows: temperature of animal holding area controlled at 22±3 C; relative humidity 30% to
70%; 12-hour light/dark cycle; controlled feed supply and free access to water; fasted overnight
prior to injection; food access allowed 4 hours after injection.
In this example, forty healthy male rats are used as subjects, randomly divided into five groups
each containing eight rats, i.e. a control group, a comparison group, an experimental group A, an
experimental group B and an experimental group C.
Hyperuricemia induction is performed by using the uricase inhibitor oxonic acid potassium salt
(0.6 g/kg/day) available from Sigma-Aldrich and uric acid (0.6 g/kg/day) available from
Sigma-Aldrich as the hyperuricemia inducing agents, which are suspended in normal saline (0.18 g
of oxonic acid potassium salt and 0.18 g of uric acid suspended in 0.5 mL normal saline), and
administered via intraperitoneal injection, two times of fixed-dose single-administration per week
lasting for four weeks.
Different groups in this example are treated as follows:
control group: 8 healthy male rats without hyperuricemia induction provided with sterilized
distilled water during the experiments;
comparison group: 8 male rats with hyperuricemia induction via four-week intraperitoneal
injection of hyperuricemia inducing agents provided with sterilized distilled water during the
experiments;
experimental group A: 8 male rats with hyperuricemia induction via four-week intraperitoneal
injection of hyperuricemia inducing agents, provided with sterilized distilled water during the
induction period and then provided with the oxygen-enriched water of the present disclosure during
one week following induction;
experimental group B: 8 male rats with hyperuricemia induction via four-week intraperitoneal
injection of hyperuricemia inducing agents, provided with the oxygen-enriched water of the present
disclosure during four-week induction and one week following induction, a total of five weeks of
oxygen-enriched water provision; and
experimental group C: 8 male rats with hyperuricemia induction via four-week intraperitoneal
injection of hyperuricemia inducing agents, provided with the oxygen-enriched water of the present
disclosure for one week prior to induction, during four-week induction and one week following
induction, a total of six weeks of oxygen-enriched water provision.
During the experiments, blood of rats in each group is collected for uric acid measurement, and
the data are listed in Table 10 below, wherein the data are represented as mean±SD, asterisk *
represents p<0.001 relative to the control group, and the uric acid unit is mg/dL.
comparison experimental experimental experimental
Day control group
group group A group B group C
7 days prior to
- - -
induction 0.93±0.19 0.99±0.22
0 day
post-induction 0.93±0.19 1.09±0.19 1.1±0.19 1.01±0.18 1.13±0.18
7th day of
induction 0.93±0.26 3±0.32* 3.11±0.23* 2.29±0.2* 1.25±0.16
14th day of
induction 1±0.2 4.13±0.39* 4.39±0.42* 2±0.28* 1.5±0.23
21st day of
induction 0.7±0.2 5.5±0.5* 5.6±0.4* 2.9±0.4* 2.5±0.3*
28th day of
induction 0.8±0.16 6.93±0.69* 7.01±0.35* 3.35±0.32* 3.08±0.24*
Table 10
The following observations can be made according to the results in Table 10: (1) after the
28-day induction period, uric acid value of the comparison group increases from 1.09 mg/dL to 6.93
mg/dL, and uric acid value of the experimental group A increases from 1.1 mg/dL to 7.01 mg/dL,
wherein the uric acid value of both groups at 7, 14, 21 and 28 days post-induction shows significant
differences relative to the control group; (2) after the 28-day induction period, uric acid value of the
experimental group B increases slightly from 1.01 mg/dL to 3.35 mg/dL, apparently lower than the
comparison group; (3) after the 28-day induction period, uric acid value of the experimental group
C increases slightly from 1.13 mg/dL to 3.08 mg/dL, apparently lower than the comparison group;
and (4) compared with the untreated control group, the experimental group C shows no significant
difference in uric acid value at 7 and 14 days post-induction.
In addition, for the comparison group, experimental group B and experimental group C,
accumulation or increased amount of uric acid in body during the induction period is calculated
according to the results in Table 10 above, and fold of uric acid accumulation of the comparison
group relative to the experimental group B or the experimental group C is calculated, by dividing
the uric acid accumulation of the comparison group with the uric acid accumulation of the
experimental group B or the experimental group C. The results are shown in Table 11 and Table 12.
comparison experimental experimental
group group B group C
7th day of
induction 2.02±0.4 1.28±0.21 0.26±0.29
14th day of
induction 3.16±0.44 1.01±0.34 0.51±0.27
21st day of
induction 4.46±0.49 1.91±0.26 1.5±0.39
28th day of
induction 5.87±0.58 2.34±0.43 2.09±0.33
Table 11
comparison group accumulation / comparison group accumulation /
experimental group B accumulation experimental group B accumulation
7th day of
induction 1.58-fold 7.77-fold
14th day of
induction 3.13-fold 6.2-fold
21st day of
induction 2.34-fold 2.97-fold
28th day of
induction 2.51-fold 2.81-fold
Table 12
Results above show that the oxygen-enriched water of the present disclosure is useful for
preventing as well as treating or curing hyperuricemia.
In addition, after completion of 4-week hyperuricemia induction of each group, the control
group and the comparison group are provided with sterilized distilled water for one week, the
experimental groups A, B and C are provided with the oxygen-enriched water of the present
disclosure for one week, and uric acid change is observed and recorded during the week, as shown
in Table 13 below, wherein 29 days post-induction represents the first day after the completion of
induction, 31 days post-induction represents the third day after the completion of induction, and so
comparison experimental experimental experimental
Day control group
group group A group B group C
28 days
post-induction 0.8±0.16 6.93±0.69* 7.01±0.35* 3.35±0.32* 3.08±0.24*
29 days
post-induction 0.9±0.2 6.2±0.4* 5.5±0.3* 2.1±0.1* 1.8±0.2*
31 days
post-induction 1.1±0.2 5.4±0.3* 2.9±0.4* 1.3±0.2 1.1±0.2
33 days
post-induction 0.9±0.3 3.95±0.2* 1.05±0.2 0.8±0.2 0.8±0.3
days
post-induction 1.1±0.2 2.2±0.2* 0.96±0.2 0.9±0.2 1±0.2
Table 13
The following observations can be made according to the results in Table 13: (1) 7 days
following the completion of induction, the comparison group shows a uric acid value of 2.2 mg/dL,
significantly higher than the control group; (2) the uric acid value of each experimental group is
significantly lower than the comparison group 1, 3, 5 and 7 days following the completion of
induction; (3) 5 days following the completion of induction, the experimental group A shows a uric
acid value (1.05 mg/dL) returning back to the normal range and maintained within the normal range
thereafter; (4) 3 days following the completion of induction, the experimental group B and the
experimental group C show a uric acid value (1.3 mg/dL and 1.1 mg/dL respectively) returning
back to the normal range and maintained within the normal range thereafter.
In addition, for the comparison group and the experimental group A, excretion or decreased
amount of uric acid in body after completion of induction is calculated according to the results in
Table 13 above, and fold of uric acid excretion of the experimental group A relative to the
comparison group is calculated, as shown in Table 14.
decreased amount of decreased amount of experimental
decreased amount of
Day experimental group group A / decreased amount of
comparison group
A comparison group
29 days
post-induction -0.74±0.93 -1.56±0.43 2.11-fold
31 days
post-induction -1.56±0.6 -4.14±0.57 2.65- fold
33 days
post-induction -2.98±0.69 -5.86±0.31 2-fold
days
post-induction -4.73±0.63 -6.05±0.42 1.28-fold
The results above indicate that the oxygen-enriched water of the present disclosure is capable
of promoting uric acid excretion and providing therapeutic effects in hyperuricemia.
The above detailed description is merely illustrative in nature and is not intended to limit the
embodiments of the subject matter or the application and uses of such embodiments. As used
herein, the term “exemplary” means “serving as an example, instance, or illustration.” Any
implementation described herein as exemplary is not necessarily to be construed as preferred or
advantageous over other implementations, unless specified otherwise.
Moreover, while at least one exemplary embodiment has been presented in the foregoing
detailed description, it should be appreciated that a vast number of variations exist. It should also
be appreciated that the exemplary one or more embodiments described herein are not intended to
limit the scope, applicability, or configuration of the claimed subject matter in any way. Rather, the
foregoing detailed description will provide those skilled in the art with a convenient guide for
implementing the described one or more embodiments. Also, the scope defined by the claims
includes known equivalents and foreseeable equivalents at the time of filing this patent application.
Claims (11)
1. An oxygen-enriched water composition comprising water and oxygen, wherein: (a) the oxygen-enriched water composition comprises an oxygen content of no less than 20 5 ppm when the oxygen content of the oxygen-enriched water composition is measured at a temperature ranging from 4 C to 50 C; (b) the oxygen content of the oxygen-enriched water composition has a temporal stability and a temperature stability that are characterized by the following features: (b1) provided that the oxygen content measured at a given time point t is 100%, the 10 oxygen content measured at 30 minutes from the given time point t is A%, and the oxygen content measured at 180 minutes from the given time point t is B%, then a difference between A% and B% is less than 24%; (b2) a decrease in the oxygen content is less than 30% when the oxygen-enriched water composition is placed under a temperature ranging from 30 C to 40 C for at least 120 15 minutes; and (b3) the oxygen content is maintained at no less than 20 ppm when the oxygen-enriched water composition is placed under a temperature ranging from 30 C to 40 C for at least 60 minutes; and (c) the oxygen-enriched water composition has a full width at half maximum between 50 Hz 20 and 70 Hz when the oxygen-enriched water composition is measured with O NMR.
2. The oxygen-enriched water composition of claim 1, wherein the oxygen content measured at 180 minutes from the given time point t is no less than 25 ppm.
3. The oxygen-enriched water composition of claim 1, wherein the oxygen content of the oxygen-enriched water composition has a temperature stability that is characterized by the following feature: 5 a decrease in the oxygen content is less than 20% when the oxygen-enriched water composition is heated from a temperature of 10 C to a temperature of 40 C.
4. The oxygen-enriched water composition of claim 1, wherein the oxygen content of the oxygen-enriched water composition has a temperature stability that is characterized by the 10 following feature: the oxygen content is no less than 25 ppm when the oxygen-enriched water composition is heated from a temperature of 10 C to a temperature of 40 C.
5. The oxygen-enriched water composition of claim 1, wherein the oxygen content of the 15 oxygen-enriched water composition has a temperature stability that is characterized by the following feature: a decrease in the oxygen content is less than 20% when the oxygen-enriched water composition is heated from a temperature ranging from 5 C to 10 C to a temperature ranging from 40 C to 50 C.
6. The oxygen-enriched water composition of claim 1, wherein the oxygen content of the oxygen-enriched water composition has a temperature stability that is characterized by the following feature: the oxygen content is maintained at no less than 30 ppm during the process of heating the oxygen-enriched water composition from a temperature ranging from 5 C to 10 C to a temperature ranging from 40 C to 50 C. 5
7. A biocompatible composition comprising the oxygen-enriched water composition of claim 1 and at least one biocompatible ingredient.
8. The biocompatible composition of claim 7, wherein the biocompatible ingredient is a therapeutic agent for treating and/or preventing hyperuricemia, or a parenteral nutrition selected 10 from the group consisting of an amino acid, fat, a saccharide, an electrolyte, a vitamin, a mineral, and any combination thereof.
9. A method of preparing the oxygen-enriched water composition of claim 1, comprising: supplying oxygen to a volume of water, which is maintained at a temperature ranging from 0 15 C to 12 C, for a period of no less than 30 minutes at a flow rate ranging from 50 cc/min to 1000 cc/min to obtain the oxygen-enriched water composition of claim 1.
10. The method of claim 9, wherein the supplying step comprises: (i) supplying oxygen to the volume of water at a first flow rate until an oxygen content of the 20 volume of water ranges from 20 ppm to 25 ppm; and (ii) supplying oxygen to the volume of water at a second flow rate that is less than the first flow rate.
11. An oxygen-enriched water composition that is prepared by the method of claim 9.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ730267A NZ730267A (en) | 2015-08-25 | 2016-08-01 | Use of oxygen-enriched water composition |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW104127596 | 2015-08-25 | ||
TW104127596A TWI529139B (en) | 2015-08-25 | 2015-08-25 | High oxygen water, biocompatible composition containing high oxygen water and preparation method of high oxygen water |
TW104128012 | 2015-08-26 | ||
TW104128012A TWI573593B (en) | 2015-08-26 | 2015-08-26 | High oxygen water in the manufacture of a medicament for the treatment and / or prevention of hyperuricemia |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ722757A NZ722757A (en) | 2017-04-28 |
NZ722757B true NZ722757B (en) | 2017-08-01 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2097993C1 (en) | Drink and method of its preparation | |
CA2937729A1 (en) | Oxygen-enriched water composition, biocompatible composition comprising the same, and methods of preparing and using the same | |
Strobusch et al. | The checkered history of lithium in medicine | |
WO2009096505A1 (en) | Agent for improving attention and concentration powers | |
CN103284261A (en) | Sports drink containing morinda officinalis and preparation method thereof | |
NZ722757B (en) | Oxygen-Enriched Water Composition, Biocompatible Composition Comprising the Same, and Methods of Preparing and Using the Same | |
CN105578901A (en) | Liquids and foodstuffs containing beta-hydroxy-beta-methylbutyrate (hmb) in free acid form | |
CN108777978A (en) | Beverage product and method and apparatus for manufacturing beverage product | |
EA032149B1 (en) | Hydrogen water with heightened antioxidant activity and methods of producing same | |
US20150224136A1 (en) | Performance-Enhancing Nasal Irrigation | |
US20210391101A1 (en) | Method of producing permanently structured water | |
CN115316670A (en) | Composition for improving skin condition, health-care beverage and preparation method | |
TWI555707B (en) | Preparation of high oxygen water | |
TWI529139B (en) | High oxygen water, biocompatible composition containing high oxygen water and preparation method of high oxygen water | |
TWI573593B (en) | High oxygen water in the manufacture of a medicament for the treatment and / or prevention of hyperuricemia | |
CN105366792B (en) | The preparation method of high-oxygen water, biocompatibility constituent and high-oxygen water containing high-oxygen water | |
KR20060086118A (en) | Tonic beverage composition comprising guarana extract | |
CN105362288B (en) | High-oxygen water is in the purposes for preparing the drug for treating and/or preventing hyperuricemia | |
JP7036503B2 (en) | Vitamin B12-containing acidic composition with excellent vitamin B12 stability | |
CN107898809A (en) | A kind of Zinc calcium gluconate oral solution and preparation method thereof | |
US20120207883A1 (en) | Alkaline booster with antioxidants | |
CN109953983A (en) | A kind of preparation method of Zinc calcium gluconate oral solution | |
JP2011132150A (en) | Antidepressant containing concentrated red wine essence as effective ingredient | |
CN103505408A (en) | Preparation method of oxiracetam glucose/sodium chloride injection | |
RU2725512C1 (en) | Low-alcohol cocktail |